ABNX — Abionyx Pharma SA Income Statement
0.000.00%
Last trade - 00:00- €121.17m
- €121.91m
- €4.55m
Annual income statement for Abionyx Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.675 | 5.25 | 4.64 | 4.55 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0.259 | 0.636 | 0.618 | 0.844 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.97 | 6.63 | 9.36 | 8.05 | 9.02 |
| Operating Profit | -2.97 | -5.95 | -4.11 | -3.41 | -4.46 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.89 | -5.82 | -4.21 | -3.52 | -4.38 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.89 | -5.82 | -4.21 | -3.52 | -4.38 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.89 | -5.82 | -4.21 | -3.52 | -4.38 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.89 | -5.82 | -4.21 | -3.52 | -4.38 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.084 | -0.234 | -0.15 | -0.12 | -0.13 |
| Dividends per Share |